

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/043088

International filing date: 23 December 2004 (23.12.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/533,367
Filing date: 29 December 2003 (29.12.2003)

Date of receipt at the International Bureau: 31 January 2005 (31.01.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1274547

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

January 19, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/533,367

FILING DATE: *December 29, 2003*

RELATED PCT APPLICATION NUMBER: *PCT/US04/43088*



Certified by

Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET**This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).****Express Mail Label No. EV 405 279 795 US**

INVENTOR(S)					
Given Name (first and middle [if any])		Family Name or Surname		Residence (City and either State or Foreign Country)	
Allan		Mishra		Menlo Park, California	
<input type="checkbox"/> Additional inventors are being named on the <u>separately numbered sheets attached hereto</u>					
TITLE OF THE INVENTION (280 characters max)					
BUFFERED PLATELET RELEASATE TO ENHANCE WOUND HEALING					
Direct all correspondence to:			CORRESPONDENCE ADDRESS		
<input checked="" type="checkbox"/> Customer Number <u>24353</u> →			<div style="border: 1px solid black; padding: 2px;">Place Customer Number Bar Code Label here</div>		
OR			Type Customer Number here		
<input type="checkbox"/> Firm or Individual Name		Bozicevic, Field & Francis LLP			
Address		200 Middlefield Road, Suite 200			
Address					
City	Menlo Park	State	California	Zip	94025
Country	U.S.A.	Telephone	(650) 327-3400	Fax	(650) 327-3231
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification Number of Pages		<u>35</u>		<input type="checkbox"/> CD(s), Number <u> </u>	
<input checked="" type="checkbox"/> Drawing(s) Number of Sheets		<u>3</u>		<input checked="" type="checkbox"/> Other (specify) <u>postcard</u>	
<input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76					
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. <input type="checkbox"/> A check or money order is enclosed to cover the filing fees <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge				FILING FEE AMOUNT \$	
filing fees or credit any overpayment to Deposit Account Number: <u>50-0815</u>				<u>80.00</u>	
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/> No <input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____					

Respectfully submitted,

Date 12/29/2003

SIGNATURE

REGISTRATION NO. 28.807

(if appropriate)

TYPED or PRINTED NAME Karl Bozicevic

Docket Number:

AMBI-005PRVTELEPHONE (650) 327-3400**USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT**

This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

BUFFERED PLATELET RELEASATE TO ENHANCE WOUND HEALING**CROSS-REFERENCE**

- [0001] This application claims priority to International Application No. PCT/US03/11623 filed April 14, 2003 (Publication No. WO 03/088905, published October 30, 2003) which claims the benefit of U.S. Provisional Application Serial No. 60/372,682, filed April 13, 2002 and U.S. Application Serial No. 10/412,821 filed April 11, 2003, which applications are incorporated herein by reference.

FIELD OF THE INVENTION

- [0002] This invention relates generally to the field of medicine and specifically to wound healing including surgical wound healing.

BACKGROUND OF THE INVENTION

- [0003] Wound healing is a complex and protracted process of tissue repair and remodeling involving many different cell types which requires a finely tuned control of various biochemical reaction cascades to balance the regenerative processes. Wound healing is generally divided into three phases: inflammation, proliferation, and maturation (Waldorf, H., and Fewkes, J., 1995, "Wound Healing," Adv. Dermatol. 10:77-96). The process comprises the migration of different cell types into the wound region, growth stimulation of epithelial cells and fibroblasts, formation of new blood vessels, and the generation of extracellular matrix. The correct functioning of these processes depends on the biological activation of various cytokines (Bennett, N. T., and Schultz, G. S., 1993, "Growth factors and wound healing: biochemical properties of growth factors and their receptors," Am. J. Surg. 165:728-37). Nutrition, the immune system, oxygen, blood volume, infection, immunosuppression, and a decrease in red blood cells are all influential factors in wound healing (Witney, J. D., 1989, "Physiological Effects of tissue oxygenation on wound healing," Heart Lung 18: 466-474).
- [0004] The quality as well as the rate of wound healing is usually dependent on the type and extent of the original injury. Three general types of process are used to treat wounds, each of which is directed to healing the damaged tissue. Closure of wounds is most commonly accomplished by suturing, although tapes, stapling or

electrocautery can also be used (Wheeless, C. R., 1996, *Wheeless' Textbook of Orthopaedics*) (Garrett, W. E., et al., 1984, *J. Hand. Surg.* 9(5):683-92). Skin tapes and various sutures each exhibit certain benefits and disadvantages in primary closure of wounds. Skin tapes cause less inflammatory reaction but fail to close the subepithelial wound spaces, while the inflammatory reaction and subsequent scarring caused by various sutures depends upon the size of the suture needle, the diameter of the suture material, and whether it is a monofilament or woven suture (Simpson, W. R., 1977, "Physiological principles of therapy in head and neck cutaneous wounds," *Laryngoscope* 87: 792-816).

[0005] In a wound, the size of an inoculum of microorganisms, the virulence of the organisms, and host antimicrobial defense mechanisms determine if an infection will develop. Thus, antibiotics can also be of therapeutic value in the treatment of wounds (Edlich, R. F., et al., 1986, "Antimicrobial treatment of minor soft tissue lacerations: a critical review," *Emergency Medical Clinics of North America* 4(3) :561-80). The pharmacological action of each antibiotic must be understood in order to choose the proper antibiotic, its route of administration, and to avoid side effects (Simpson, W. R., *supra*). Recent results suggest that antibiotic therapy allows cell proliferation and differentiation to proceed more rapidly and thus may be helpful in augmenting wound repair (Barrow, R. E., et al., 1994, "Efficacy of cefazolin in promoting ovine tracheal epithelial repair," *Respiration* 61:231-5; Maeder, K., et al., 1993, "Methicillin-resistant *Staphylococcus aureus* (MRSA) colonization in patients with spinal cord injury," *Paraplegia* 31: 639-44). Proteolytic enzymes have also been used as adjuncts to antibiotic treatment of contaminated wounds (Rodeheaver, G. T., et al., 1978, "Mechanisms by which proteolytic enzymes prolong the golden period of antibiotic action," *Am. J. Surg.* 136(3) :379-82).

[0006] The topical administration of specific, recombinantly produced cytokines, including bFGF, EGF, PDGF, and TGF- β , may considerably accelerate wound healing (Moulin, V., 1995, "Growth factors in skin wound healing," *Eur. J. Cell. Biol.* 68:1-7). Growth factors attract cells into the wound, stimulate their proliferation, and have profound influence on extracellular matrix deposition. Since developing the ability to mass-produce these cytokines by recombinant techniques,

many studies have demonstrated that growth factors can augment all aspects of tissue repair in normal and impaired healing models (e.g., Schultz, G. S., et al., 1987, "Epithelial wound healing enhanced by transforming growth factor-alpha and vaccinia growth factor," *Science* 235: 350-2; Deuel, T. F., et al., 1991, "Growth factor and wound healing: platelet derived growth factor as a model cytokine," *Annu. Rev. Med.* 42: 567-84). Although preliminary clinical trials have shown that growth factor treatment has occasionally led to statistically significant improvements in tissue repair, it is not clear that these results are clinically significant, and it has been suggested that new clinical trials must focus on targeting growth factors for specific types of impaired healing (Greenhalgh, D. G., 1996, "The role of growth factors in wound healing," *J. Trauma* 41:159-67).

CHRONIC INFLAMMATION

[0007] Natural, humoral, and cellular immune mechanisms have all been implicated in the pathogenesis of chronic inflammatory diseases (Seymour, G. J., et al., 1979, "The immunopathogenesis of progressive chronic inflammatory periodontal disease, 1979, "J. Oral Pathol. 8:249-65). Autoimmune diseases result from abnormalities in lymphocyte function. Abnormalities in T cell function can be responsible for disease through cell-mediated immunity, and the activity of helper T cells in the production of antibodies may contribute to autoantibody formation. The central role of helper T cells in autoimmune disease is supported by the association of many of these diseases with certain HLA molecules. The failure of one or more steps in the maintenance of tolerance could result in autoimmunity (Robinson, D. R., 1996, "Immunologic Tolerance and Autoimmunity," in: *Scientific American Medicine*, Vol. 2, Section VI, Scientific American Press, New York, p.1-11).

[0008] Several types of treatment are used in autoimmune disease, all of which are directed at lessening the immune response in the affected tissue. For example, treatment for rheumatoid arthritis, an autoimmune disease, can utilize anti-inflammatory agents such as nonsteroidal anti-inflammatory agents (NSAIDs) or glucocorticosteroids, remission inducing agents such as gold salts, and/or immunosuppressive drugs such as cyclophosphamide. Orthopedic surgery can also be used to replace joints damaged during the inflammatory process (see Gilliland, B. C., and Mannik, M., 1983, "Rheumatoid Arthritis" In: *Harrison's Principles of*

Internal Medicine, McGraw Hill, New York, P. 1977-1984). Recent work has suggested the possibilities of new treatments, also directed to the affected tissue, such as the use of TNF alpha in the treatment of rheumatoid arthritis (Brennan, F. M., et al., 1995, "Cytokine expression in chronic inflammatory disease," Br. Med. Bull. 51:368-384).

[0009] Allergy refers to a condition in which the immune response to environmental antigens causes tissue inflammation and organ disfunction. As in the autoimmune diseases, the data suggest an interaction of several components of the immune system in allergic diseases. The diversity of expression of allergic diseases arises from different immunologic effector mechanisms, which evoke specific patterns of tissue injury (Beer, D. J. et al., 1996. "Allergy," In: Scientific American Medicine, Vol. 2, Section VII, Scientific American Press, New York, P. 1-29). The clinical features of each allergic disease reflect the immunologically mediated inflammatory response in the affected organs or tissues (e.g. asthma reflects an inflammatory response in the lungs).

[0010] Several treatment strategies are used to treat the immune-mediated allergic diseases, all of which are directed at lessening the immune response in the inflamed tissue. For example, in the treatment of asthma, therapy can involve environmental control, pharmacotherapy, and allergin immunotherapy (Beer, D. J., et al., 1996, "Allergy," In: Scientific American Medicine, Vol. 2, Section VII, Scientific American Press, New York, P. 1-29). In the treatment of asthma, elimination of the causative agent is the most successful means of preventing the inflammation. However, this is often not possible, and thus several classes of drugs have been used. These include the methylxanthines (for bronchodilation), adrenergic stimulants (stimulation of .beta.-adrenergic receptors, bronchodilators), glucocorticoids (lessen inflammation in the lung), chromones (downregulate mast cells, lessen inflammation in the lung), and anticholinergics (bronchodilators)(McFadden, E. R., Jr., and Austen, K. F., "Lung disease caused by immunologic and environmental injury," In: Harrison's Principles of Internal Medicine, McGraw Hill, New York, p. 1512-1519). Desensitization or immunotherapy with extracts of the suspected allergens has also been suggested in order to reduce inflammation in asthma (McFadden and Austen, op. cit.; Jacquemin, M. G., and Saint-Remy, J. M., 1995, "Specific down-regulation of anti-allergen IgE and IgG antibodies in humans

associated with injections of allergen-specific antibody complexes," Ther. Immunol. 2:41-52).

SUMMARY OF THE INVENTION

- [0011] A blood component such platelets are isolated from a patient's blood, concentrated, and formulated in a pH adjusted formulation. The formulation is administered to a wound and/or area of inflammation in order to promote healing and modulate the inflammatory response. The formulation may be directly applied to the surface of a surgical wound.
- [0012] An aspect of the invention is an isolated, formulated blood component used in the treatment of a surgical wound.
- [0013] Another aspect of the invention is a formulation of blood platelets treated by a method such as sonification to obtain a releasate which is pH balanced.
- [0014] Yet another aspect of the invention is a pH balanced platelet releasate formulation applied to a wound and/or area of inflammation.
- [0015] Still another aspect of the invention is a method of improving results obtained with a surgical procedure by applying a formulation of the invention to the site of surgical incision before, during and/or after the incision is made.
- [0016] Another aspect of the invention is a blood concentrate formulation of the invention mixed with and/or administered with collagen to improve wound healing and/or to modulate inflammation.
- [0017] These and other objects, advantages, and features of the invention will become apparent to those persons skilled in the art upon reading the details of the embodiments as more fully described below.

BRIEF DESCRIPTION OF THE DRAWINGS

- [0018] The invention is best understood from the following detailed description when read in conjunction with the accompanying drawings. It is emphasized that, according to common practice, the various features of the drawings are not to-scale. On the contrary, the dimensions of the various features are arbitrarily expanded or reduced for clarity. Included in the drawings are the following figures:
- [0019] Figure 1 is a graph of cell count versus time for cultured fibroblast cells in PRP.

[0020] Figure 2 is a graph of cell count for three different concentrations of PRP releasate and a control.

[0021] Figure 3 is a graph of cell counts over seven days for a control and a culture with sonicated PRP.

DETAILED DESCRIPTION OF THE INVENTION

[0022] Before the present formulations and methods are described, it is to be understood that this invention is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.

[0023] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limits of that range is also specifically disclosed. Each smaller range between any stated value or intervening value in a stated range and any other stated or intervening value in that stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range, and each range where either, neither or both limits are included in the smaller ranges is also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.

[0024] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited.

[0025] It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates

otherwise. Thus, for example, reference to "a surgical incision" includes a plurality of such incisions and reference to "the area of inflammation" includes reference to one or more areas and equivalents thereof known to those skilled in the art, and so forth.

[0026] The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.

DEFINITIONS

[0027] The term "platelet" is used here to refer to a blood platelet. A platelet can be described as a minisule protoplasmic disk occurring in vertebrate blood. Platelets play a role in blood clotting. The platelet may be derived from any source including a human blood supply, or the patient's own blood. Thus, the platelets in the composition of the inventions may be autologous. The platelets may be homologous, i.e. form a human but not the same human being treated with the composition.

[0028] The terms "treatment", "treating" and the like are used herein to generally mean obtaining a desired pharmacologic, physiologic or cosmetic effect. The effect may be prophylactic in terms of completely or partially preventing a condition, appearance or symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a condition and/or adverse effect attributable to a condition or disease. "Treatment" as used herein covers any treatment of a condition, disease or undesirable appearance in a mammal, particularly a human, and includes:

- (a) preventing the disease, condition or appearance such as wrinkles from occurring in a subject which may be predisposed to such but has not yet been observed or diagnosed as having it;
- (b) inhibiting the disease, condition or appearance, i.e., causing regression of condition or appearance.

- (c) relieving the disease, condition or undesired appearance, i.e., causing regression of condition or appearance.

[0029] The invention is directed toward treating patients with skin diseases, undesirable skin conditions or appearances and is particularly directed toward treating older skin to provide a younger appearance, i.e., preventing, inhibiting or relieving the effects of aging on skin and thereby improving the appearance of wrinkled, lined, dry, flaky, aged or photodamaged skin and improving skin thickness, elasticity, flexibility and/or plumpness at one or more particular sites. More specifically, "treatment" is intended to mean providing a therapeutically detectable and beneficial effect on a patient suffering from a skin condition or appearance which the patient has found to be undesirable.

[0030] The terms "synergistic", "synergistic effect" and like are used herein to describe improved treatment effects obtained by combining one or more active components together in a composition or in a method of treatment. Although a synergistic effect in some field is meant an effect which is more than additive (e.g., $1+1=3$) in the field of skin treatment an additive ($1+1=2$) or less than additive ($1+1=1.6$) effect may be synergistic. For example, if one active ingredient removed 50% of a wrinkle and a second active ingredient removed 50% of a wrinkle the combined (and merely additional) effect would be 100% removal of the wrinkle. However, the effect of both would not be expected to remove 100% of the wrinkle. Often, two active ingredients have no better or even worse results than either component by itself. If an additive effect could be obtained with such treatments than multiple ingredients could be applied to completely remove all wrinkles and such is not the case.

[0031] The term "platelet-rich-plasma," "PRP" and the like are used interchangeable here to mean a concentration of platelets in a carrier which concentration is above that of platelets normally found in blood. For example, the platelet concentration may be 5 times, 10 times, 100 times or more the normal concentration in blood. The PRP may use the patient's own plasma as the carrier and the platelets may be present in the plasma at a range of from about 200,000 or less to 2,000,000 or more platelets per cubic centimeter. The PRP may be formed from whole blood e.g. by technology disclosed in any of 5,614,106; 5,580,465; 5,258,126 or publication cited in these patents and if needed stored by technology

as taught in 2002/0034722A1; 5,622,867 or publications cited therein. The PRP may comprise blood component other than platelets. It may be 50% or more, 75% or more, 80% or more, 95% or more, 99% or more platelets. The non-platelet components may be plasma, white blood cells and/or any blood component. PRP is formed from the concentration of platelets from whole blood, and may be obtained using autologous, allogenic, or pooled sources of platelets and/or plasma. PRP may be formed from a variety of animal sources, including human sources.

[0032] The "dose" of platelets administered to a patient will vary over a wide range based on the age, weight, sex and condition of the patient as well as the patients' own normal platelet concentration, which as indicated above can vary over a ten fold or greater range. Doses of 1 million to 5 million platelets are typical but may be less or greater than such by a factor of two, five, ten or more.

[0033] The term "platelet releasate" is the PRP as defined above but treated so that what is inside the platelet shells is allowed to come out. The releasate may be subjected to processing whereby the platelet shells are removed and/or other blood components are removed, e.g. white blood cells and/or red blood cells or remaining plasma is removed. The pH of the platelet releasate may be adjusted to physiological pH or higher or to about $7.4 \pm 10\%$, $7.4 \pm 5\%$, $7.4 \pm 2\%$ or 7.4 to 7.6 as needed.

[0034] The term "iontophoresis" means the migration of ionizable molecules through a medium driven by an applied low level electrical potential. This electrically mediated movement of molecules into tissues and in particular into the skin is in addition to the movement obtained via concentration gradient dependent diffusion. If the tissue (e.g. skin) through which the molecules travel also carries a charge, some electro-osmotic flow occurs. However, generally, the rate of migration of molecules with a net negative charge towards the positive electrode and vice versa is determined by the net charge on the moving molecules and the applied electrical potential. The driving force may also be considered as electrostatic repulsion. Iontophoresis usually requires relatively low constant DC current in the range of from about 2-5 mA. For enhancing the delivery of a formulation of the invention such and a platelet releasate through the skin (transdermal iontophoresis), one electrode is positioned over the treatment area and the second electrode is located at a remote site, usually somewhere else on the skin.

The return electrode may, for certain applications, be placed elsewhere on the skin as the iontophoretic delivery electrode. With the present invention the return electrode may be similarly positioned on the skin. The applied potential for iontophoresis will depend upon number of factors, such as the electrode configuration and position on the tissue (skin), the nature and charge characteristics of the molecules (e.g. releasate formulation) to be delivered, and the presence of other ionic species within components of the patch and in the tissue extracellular compartments.

[0035] As used herein "Collagen" means pharmaceutical grade collagen used in the treatment of human patients. Collagen is a fibrous protein that form fibrils having a very high tensile strength and that has been found in most multicellular organisms. Collagen serves to hold cells and tissues together and to direct the development of mature tissue. Collagen is the major fibrous protein in skin, cartilage, bone, tendon, blood vessels and teeth.

[0036] There are many types of collagen which differ from each other to meet the requirements of various tissues. Some examples of types of collagen are as follows: type one $[\alpha 1(I)]_2 \alpha 2$ which is found in skin, tendon, bone and cornea; type two $[\alpha 1(II)]_3$ which is found in cartilage intervertebral disc, and the vitreous body; type three $[\alpha 1(III)]_3$ which can be found in skin and the cardiovascular system; type four $[\alpha 1(IV)]_2 \alpha 2(IV)$ which can be found in basement membrane; type five $[\alpha 1(V)]_2 \alpha 2(V)$ and $\alpha 1(V) \alpha 2(V) \alpha 3(V)$ which is found in the placenta and cornea. Examples of newly identified forms of collagen include: type seven (VII) which is found in anchoring fibrils beneath many epithelial; and types nine (IX), ten (X) and eleven (XI), which are minor constituents of cartilage.

[0037] The chemical characterization of native collagen was difficult since its low solubility made isolation of collagen a tedious task. Eventually, it was discovered that collagen from tissues of young animals was not as extensively cross linked as that of mature tissues and thus was more amenable to extraction. For example, the basic structural unit of type I collagen, tropo-collagen, can be extracted in intact form from some young, collagen-containing animal tissues.

[0038] Substantial information can be found in patents and publications relating to uses of Collagen. For example, see US patents 4,294,241; 4,668,516; 5,640,941;

and 5,716,411 all of which are incorporated herein by reference as are the publications and patents cited in these patents to disclose and describe various ways of using collagen which can in turn be mixed with and administered and used with platelet formulations of the present invention.

INVENTION IN GENERAL

- [0039] Formulations of the invention can be applied topically to and/or injected into and/or under a wound or area of inflammation. The formulations comprise platelet and/or fibroblast cells each alone or each individually or in combination combined with collagen. The platelets and fibroblast cells are preferably obtained from the patient to which the formulation is being administered. A formulation of the invention can be administered to any skin, e.g. to cut, scraped and inflamed skin. A range of beneficial results may be obtained, e.g. improving the rate of healing and modulating the inflammatory response.
- [0040] A formulation of the invention may be produced by drawing blood from a human; and centrifuging the blood to obtain a plasma-rich fraction or PRP. The platelet-rich plasma is then combined with a dermatologically acceptable carrier which may be collagen suitable for injection into humans.
- [0041] In an aspect, the invention relates to the method wherein the platelet composition is at or above physiological pH. In an aspect, the invention relates to the method wherein the platelet composition optionally includes platelet releasate. In an aspect, the invention relates to the method further comprising: mixing into the platelet composition one or more of the ingredients selected from thrombin, epinephrine, collagen, calcium salts, pH or adjusting agents. Also useful are materials to promote degranulation or preserve platelets, additional growth factors or growth factor inhibitors, small molecule pharmaceuticals such as NSAIDS, steroids, and anti-infective agents.
- [0042] In an aspect, the invention relates to the method with the proviso that the platelet composition is substantially free from exogenous activators prior to its administration onto or into the skin.

ADDITIONAL ACTIVE COMPONENTS

[0043] There are a number of compounds which can have a beneficial effect on treating skin. The effect of those components can be enhanced when combined in a composition of the invention. The composition may be any blood component concentrate such as platelets or platelet releasate which may be mixed into an injectable form of collagen. The collagen/platelet composition may be supplemented with one or more components. For example, further beneficial results may be obtained by combining the compositions according to the invention with at least one substance chosen from vitamins, particularly the vitamins of group A (retinol) and group C and derivatives thereof such as the esters, especially the palmitates and propionates, tocopherols, xanthines, particularly caffeine or theophylline, retinoids, particularly vitamin A acid, extracts of *Centella asiatica*, Asiatic and madecassic acids and glycosylated derivatives thereof such as asiaticoside or madecassoside, extracts of *Siegesbeckia orientalis*, extracts of *Commiphora mukl* and extracts of *Eriobotrya japonica*, cosmetically acceptable silicon derivatives such as polysiloxanes, silanols and silicones, C₃ – C₁₂ aliphatic alpha-keto acids, particularly pyruvic acid, C₂ – C₁₂ aliphatic alpha-hydroxy acids, particularly citric acid, glycolic acid, malic acid and lactic acid, lipoic acid, amino acids, particularly arginine, citrulline and threonine, ceramides, glycoceramides, sphingogoline derivative, particularly type II and III ceramides, phospholipids, forskolin and derivatives thereof, extracts of *Coleus*, extracts of *Tephrosia*, elastase inhibitors, particularly ellagic acid and soya peptides, collagenase inhibitors, particularly plant peptides and extracts such as extracts of roots of *Coptidis* and extracts of roots of *Scutellaria baicalensis* Georgi, flavonoids such as wogonin, baicalin and abaicalein, aqueous-ethanolic extracts of leaves of *Ginkgo biloba*, *Mosla chinensis*, *Salvia officinalis* and *Cinnamomum cassia*, catechuic extracts of *Camellia sinensis* and aqueous extracts of bean shells of *Theobroma cacao*, anti-inflammatories, particularly phospholipase A2 inhibitors, soothing agents, particularly extracts of liquorice, glycyrrhetic acid and ammonium glycyrrhizinate, hydrating agents, particularly polypols, propylene glycol, butylenes glycol, glycerol and hyaluronic acid, agents for combating stretch marks, particularly extracts of horse chestnut and escin, agents for protecting or improving the microcirculation, particularly bioflavonoids from *Ginkgo biloba*, isodon,

extracts of *Ami visnaga*, visnadine and ruscogenin, free radical inhibitors, particularly polyphenols such as PCO (procyanidolic oligomers) and derivatives thereof and plant extracts, particularly extracts of *Curuma longa*, antiseborrhea agents, such as a 5-alpha-reductase inhibitor, particularly an extract of *Pygeum africanum*, and stimulants of the microcirculation of the blood, such as cepharanthine and methyl nicotinate.

[0044] The compositions according to the invention can advantageously contain substances for protecting the skin from the harmful effects of the sun, such as solar filters, individually or in combination, especially UV A filters and UV B filters, particularly titanium oxides and zinc oxides, oxybenzone, Parsol MCX, Parsol 1789 and filters of vegetable origin, substances for limiting the damage caused to the DNA, particularly those for limiting the formation of thymine dimmers, such as ascorbic acid and derivatives thereof and/or Photonyl.RTM., and substances for contributing to the elimination of liver spots, such as inhibitors of melamin or tyrosinase synthesis.

[0045] The invention also relates to the method further comprising: mixing into the platelet composition substantially simultaneously with its topical application to the skin, with one or more of the ingredients selected from thrombin, epinephrine, collagen, calcium salts, and pH adjusting agents. Also useful are materials to promote degranulation or preserve platelets, additional growth factors or growth factor inhibitors, small molecule pharmaceuticals such as NSAIDS, steroids, and anti-infective agents.

[0046] In yet another aspect, the invention relates to a dermatological composition comprising: platelet releasate wherein the composition is at a pH greater than or equal to physiological pH, and wherein the composition comprises substantially no unactivated platelets.

[0047] Platelets are cytoplasmic portions of marrow megakaryocytes. They have no nucleus for replication; the expected lifetime of a platelet is some five to nine days. Platelets are involved in the hemostatic process and release several initiators of the coagulation cascade. Platelets also release cytokines involved with initiating wound healing. The cytokines are stored in alpha granules in platelets. In response to platelet to platelet aggregation or platelet to connective tissue contact, as would be expected in injury or surgery, the cell membrane of the platelet is "activated" to

secrete the contents of the alpha granules. The alpha granules release cytokines via active secretion through the platelet cell membrane as histones and carbohydrate side chains are added to the protein backbone to form the complete cytokine. Platelet disruption or fragmentation, therefore, does not result in release of the complete cytokine.

[0048] A wide variety of cytokines are released by activated platelets. Platelet derived growth factor (PDGF), transforming growth factor-beta (TGF-b), platelet-derived angiogenesis factor (PDAF) and platelet derived endothelial cell growth factor (PD-ECGF) and insulin-like growth factor (IGF) are among the cytokines released by degranulating platelets. These cytokines serve a number of different functions in the healing process, including helping to stimulate cell division at an injury site. They also work as powerful chemotactic factors for mesenchymal cells, monocytes and fibroblasts, among others.

[0049] Historically, PRP has been used to form a fibrin tissue adhesive through activation of the PRP using thrombin and calcium, as disclosed in U.S. Patents 5,165,938 to Knighton, and 5,599,558 to Gordinier et al., incorporated in their entirety by reference herein. Activation results in release of the various cytokines and also creates a clotting reaction within various constituents of the plasma fraction. The clotting reaction rapidly forms a platelet gel (PG) which can be applied to various wound surfaces for purposes of hemostasis, sealing, and adhesion.

[0050] In another embodiment, the inventive platelet composition may comprise releasate from platelets, in addition to platelets themselves. The releasate comprises the various cytokines released by degranulating platelets upon activation. Many activators of platelets exist; these include calcium ions, thrombin, collagen, epinephrine, and adenosine diphosphate. Releasates according to the invention may be prepared according to conventional methods, including those methods described in U.S. Patents 5,165,938 to Knighton, and 5,599,558 to Gordinier et al. The releasates alone or in a dermatologically acceptable carrier may be topically applied and/or injected into the skin.

[0051] One disadvantage of conventional releasate strategies associated with the use of PRP as PG is the use of thrombin as a preferred activator. In particular, much thrombin used in PG is bovine thrombin, which can create problems due to

contamination issues regarding prions which cause Creutzfeldt-Jakob disease.

Many bovine materials are suspect due to possible prion contamination, and so use of bovine thrombin is disfavored. Human pooled thrombin is likewise disfavored due to the potential of contamination with various infectious agents such as viruses, prions, bacteria and the like. Recombinant human thrombin might also be used, but may be expensive. Any of the platelets, fibroblast cells, thrombin, or formulations of the invention or components thereof may be tested for the presence of prions using assays known in the art such as disclosed in U.S. Patents 6,620,629 issued September 16, 2003 and; 6,221,614; 6,617,119 issued September 9, 2003; and 5,891,641.

[0052] It is a particular advantage of the present invention that exogenous or extra activators need not be administered to a patient. Collagen, a major component of connective tissues, is a strong activator of platelets. Thus, when the inventive platelet composition is administered to skin, platelets in the platelet composition may bind to the collagen and then be activated. This reduces or eliminates the need for administering an exogenous activator such as thrombin. The disadvantages of thrombin use have been noted above. Other strong activators, such as calcium ions, can cause severe pain, unintentional clotting, and other undesirable side effects. Thus, in an embodiment of the invention, no or substantially no exogenous activator is present or added as part of the inventive platelet composition, or is used in the preparation of the inventive platelet composition. Of course, exogenous activators may still be employed if a physician determines that they are medically necessary or desirable. Thus, the composition of the invention may consist only of platelets as the active ingredient.

[0053] The platelet composition may be prepared using any conventional method of isolating platelets from whole blood or platelet-containing blood fractions. These include centrifugal methods, filtration, affinity columns, and the like. If the platelet composition comprises PRP, then conventional methods of obtaining PRP, such as those disclosed in U.S. Patents 5,585,007 and 5,788,662 both to Antanavich et al., incorporated herein by reference in their entirety, may be utilized.

[0054] Adjusting the pH of platelet compositions has been used to prolong the storage time of unactivated platelets, as disclosed in U.S. Patents 5,147,776 to Koerner, Jr. and 5,474,891 to Murphy, incorporated by reference herein. pH may

be adjusted using a variety of pH adjusting agents, which are preferably physiologically tolerated buffers, but may also include other agents that modify PRP pH including agents that modify lactic acid production by stored platelets. Especially useful are those pH adjusting agents that result in the pH of the platelet composition becoming greater than or equal to physiological pH. In an embodiment, the pH adjustment agent comprises sodium bicarbonate. Physiological pH, for the purposes of this invention, may be defined as being a pH ranging from about 7.35 to about 7.45. pH adjusting agents useful in the practice of this invention include bicarbonate buffers (such as sodium bicarbonate), calcium gluconate, choline chloride, dextrose (d-glucose), ethylenebis(oxyethylenenitrilo)tetraacetic acid (EGTA), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), maleic acid, 4-morpholinepropanesulfonic acid (MOPS), 1,4-piperazinebis(ethanesulfonic acid) (PIPES), sucrose, N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES), tris(hydroxymethyl)aminomethane (TRIS BASE), tris(hydroxymethyl)aminomethane hydrochloride (TRIS.HCl), and urea. In a preferable embodiment, the pH adjusting agent is a bicarbonate buffer, more preferably, sodium bicarbonate.

PLATELET ALLOIMMUNIZATION

[0055] Platelets present a variety of antigens, including HLA and platelet-specific antigens. Patients transfused with platelets which are not their own often develop HLA antibodies. The patient may become refractory to all but HLA-matched platelets. When platelets are transfused to a patient with an antibody specific for an expressed antigen, the survival time of the transfused platelets may be markedly shortened. Nonimmune events may also contribute to reduced platelet survival. It is possible to distinguish immune from nonimmune platelet refractoriness by assessing platelet recovery soon after infusion, i.e., 10 - 60 minutes postinfusion platelet increment. In immune refractory states secondary to serologic incompatibility, there is poor recovery in the early postinfusion interval. In nonimmune mechanisms, i.e., splenomegaly, sepsis, fever, intravascular devices, and DIC, platelet recovery within 1 hour of infusion may be adequate while long-

term survival (i.e., 24-hour survival) is reduced. Serologic tests may be helpful in selecting platelets with acceptable survival. In accordance with the present invention the platelets are preferably taken from the same patient they will be used to treat. In a similar manner the platelet releasate or any portion thereof is taken from the same patient treated with the formulation. Alternatively, the patient is treated with platelets, platelet releasate and portions thereof extracted from a donor patient tested for and found to have a close serologic match with the patient being treated.

CELL CULTURES

- [0056] The cell cultures of the present invention involved the use of PRP and, for example may use PRP from the same patient the cells (e.g. fibroblast cells) being cultured were obtained from. Conventional cell culture medium may be supplemented with one or more concentrated blood components such as platelets, platelet releasate, white blood cells, and/or releasate obtained from white blood cells or a particular class or group of white blood cells.
- [0057] Example 5 below shows the cell culture with PRP therein and Example 6 shows the cell culture with three different concentrations of platelet releasate therein. The platelets may be treated in any manner to open the platelets or allow the releasate to escape. The treatment may be with an energy wave (e.g. ultra sound), agitation, temperature (heating/cooling- freezing/thawing), and chemical treatments or any combination thereof.
- [0058] Many kinds of cells can be grown in culture, provided that suitable nutrients and other conditions for growth are supplied. Thus, since 1907 when Harrison noticed that nerve tissue explanted from frog embryos into dishes under clotted frog lymph developed axonal processes, scientists have made copious use of cultured tissues and cells from a variety of sources. Such cultures have been used to study genetic, physiological, and other phenomena, as well as to manufacture certain macromolecules using various fermentation techniques known in the art.
- [0059] In studies of mammalian cell biology, cell cultures derived from lymph nodes, muscle, connective tissue, kidney, dermis and other tissue sources have been used. Generally speaking, the tissue sources that have been most susceptible to the preparation of cell cultures for studies are derivatives of the ancestor mesodermal

cells of early development. Tissues that are the progeny of the ancestor endodermal and ectodermal cells have only in recent years become amenable to cell culture, of a limited sort only. The cell types derived from the endoderm and ectoderm of early development include epidermis, hair, nails, brain, nervous system, inner lining of the digestive tract, various glands, and others. Essentially, long-term cultures of normal differentiated human cells, particular certain types of cells, are difficult to obtain. For various types of cartilage cultures see U.S. Patent 5,902,741 issued May 11, 1999.

[0060] The cell-types subjected to a procedure of the present invention are derived from various tissues, can be of human origin or that of any other mammal, and may be of any suitable source, such as fibroblast cells, stem cells, cell from a whole pancreas, parotid gland, thyroid gland, parathyroid gland, prostate gland, lachrymal gland, cartilage, kidney, inner ear, liver, parathyroid gland, oral mucosa, sweat gland, hair follicle, adrenal cortex, urethra, and bladder, or portions or multiples thereof.

[0061] The tissue is prepared using any suitable method, such as by gently teasing apart the excised tissue or by digestion of excised tissue with collagenase via, for example, perfusion through a duct or simple incubation of, for example, teased tissue in a collagenase-containing buffer of suitable pH and tonic strength. The prepared tissue then is concentrated using suitable methods and materials, such as centrifugation through ficol gradients for concentration (and partial purification). The concentrated tissue then is resuspended into any suitable vessel, such as tissue culture glassware or plasticware. The resuspended material may include whole substructures of the tissue, cells and clusters of cells. For example, such substructures may include fibroblast cells.

[0062] The initial culture of resuspended tissue cells is a primary culture. In the initial culturing of the primary culture, the cells attach and spread on the surface of a suitable culture vessel with concomitant cell division. Subsequent to the initial culture, and usually after the realization of a monolayer of cells in the culture vessel, serially propagated secondary and subsequent cultures are prepared by dissociating the cells of the primary culture and diluting the initial culture or its succeeding cultures into fresh culture vessels, a procedure known in the art as passaging. Such passaging results in an expanded culture of cells of the originating

tissue. The cell culture is passaged at suitable intervals, such as about once a week or after about two to about three cell divisions of the cultured cells. Longer intervals of two to three weeks or shorter intervals of two to three days would suffice also. For passaging the cell cultures, a dilution of the cultured cells at a ratio of from about 1:2 to about 1:100 is used. Preferably, a ratio of from about 1:4 to about 1:50 is used. More preferably, a ratio of from about 1:4 to about 1:6 is used.

[0063] The concentrated prepared tissue, which may be in the form of free cells and/or clumps (where the clumps may constitute ordered substructures of the tissue) is resuspended at any suitable initial cell or presumptive cell density. Suitable cell densities range from about 100 cells to about 1000 cells per square centimeter of surface area of the culture vessel. For useful vessels see U.S. Patent 5,274,084 issued December 21, 1993 and patents and publications cited therein.

[0064] Basal media that may be used include those commercially available from Sigma Chemical Co., Life Technologies, Inc., or BioWhittaker Co. Any basal medium may be used provided that at least magnesium ion, calcium ion, zinc ion, bicarbonate ion, potassium ion, and sugar levels can be manipulated to a lower or higher concentration in the resultant medium; in particular, the magnesium ion, calcium ion, bicarbonate ion, and D-glucose levels are required at a lower concentration, zinc ion is required at the same or higher concentration, and potassium ion is required at the same or lower concentration than is usual in standard basal media.

[0065] Preferred levels of magnesium ion, as contributed by suitable magnesium salts, such as $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ and $\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$, are between 60 and 240 mg/L; more preferred levels of magnesium salts are between 100 and 150 mg/L. Preferred levels of calcium ion, as contributed by suitable calcium salts, such as $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$, are between 25 and 200 mg/L; more preferred levels of calcium ion are between 40 and 125 mg/L. Preferred levels of zinc ion, as contributed by suitable zinc salts, such as $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$, are between 0.1 and 0.5 mg/L; more preferred levels of zinc ion are between 0.12 and 0.40 mg/L; yet more preferred levels of zinc ion are between 0.15 and 0.20 mg/L. Preferred levels of ascorbic acid are between 30 and 125 mg/L; more preferred levels of ascorbic acid are between 40 and 100 mg/L. Preferred levels of bicarbonate ion, as contributed by suitable bicarbonate salts, such as sodium bicarbonate, are between

175 and 700 mg/L; more preferred levels of bicarbonate ion are between 300 and 400 mg/L. Preferred levels of potassium ion, as contributed by suitable potassium salts, such as potassium chloride, are between 100 and 400 mg/L; preferred levels of potassium ion are between 200 and 325 mg/L; most preferred levels of potassium ion are between 210 and 250 mg/L. Preferred levels of sugar, as contributed by a suitable sugar, such as D-glucose, are between 400 and 1800 mg/L; more preferred levels of sugar are between 600 and 1200 mg/L; most preferred levels of sugar are between 800 and 1000 mg/L. Preferred levels of human placental lactogen are between 3 and 15 .mu.g/ml; more preferred levels of human placental lactogen are between 4 and 13 .mu.g/ml; most preferred levels of human placental lactogen are between 8 and 12 .mu.g/ml. Preferred levels of insulin, as contributed by a suitable naturally-isolated, clonally-derived, or synthesized insulin, such as isolated bovine sodium-insulin, are between 50 and 20,000 ng/ml; more preferred levels of insulin are between 100 and 10,000 ng/ml; most preferred levels of insulin are between 500 and 5,000 ng/ml. (See U.S. Patent 6,008,047 issued December 28, 1999)

[0066] The cells such as fibroblasts and keratinocytes used in accordance with the present invention may be either autogenic or allogenic. The use of allogenic cells enables the production and storage of the living skin equivalent of the present invention thereby avoiding delays in procuring grafts for the treatment of wounds. Both cell types, keratinocytes and fibroblasts could be stored frozen for months as single cell suspensions, using published methods. After thawing these cells should maintain their viability and grow readily in culture. (See U.S. Patent 6,039,760 issued March 21, 2000)

TOPICAL FORMULATIONS

- [0067] The PRP obtained can be dispersed in, mixed with or combined in any fashion with a dermatologically acceptable carrier to create a topical formulation. The formulation may be an ointment, cream, lotion, oil or the like that can be placed on the surface of a wound. The carrier may be comprised of collagen and/or natural, refined or synthetic oils. The carrier may be derived from a liquid petroleum gelled by the addition of a polyethylene resin. Composition based on animal fats, and/or vegetable oils may be used including lard, benzoinated lard, olive oil, cottonseed oil and the like. Examples of topical formulations are described and disclosed in publications such as Remington's Pharmaceutical Sciences, (18th Ed.) Mack Publishing, Co. 1990. Such formulations may comprise a preservative and bactericidal and/or bacteriostatic compounds as well as perfumes and coloring agents.
- [0068] The topical formulations may have a buffer added to the PRP or have the buffer in the carrier. The pH of the formulation should be balanced to obtain a pH close to physiological pH e.g. about $7.4 \pm 10\%$ or $\pm 5\%$, or 7.2 to 7.6.
- [0069] The presence of other active ingredients may require a different overall pH for the formulation as some active ingredients require a particular pH range. The releasate, platelets and/or the platelet and releasate may be combined with the carrier over a wide range of concentrations, e.g. 1%, 10%, 25%, 50%, 75%, 90%, 95%, 99% carrier with the remainder being PRP, platelets, platelet releasate or combinations thereof with or without an additional active ingredient.

TRANSDERMAL PATCH

- [0070] FIG. 4 shows a first type of transdermal patch 1 which includes an impermeable support film 2 on which a matrix 3 is arranged. The matrix may be comprised of collagen. The active substance which is a blood concentrate such as PRP or platelet releasate, and/or combinations thereof, is dissolved and/or dispersed in the matrix 3 which serves as a reservoir. The matrix 3, on the opposite side to the impermeable support film 2, is covered by a membrane 4 permeable to the blood concentrate, which regulates the cross-flow. This membrane may not be necessary if the degree of permeation of the blood concentrate such as PRP or platelet releasate in the skin does not exceed the values which might cause side effects.

[0071] The degree of diffusion of the active substance (e.g. blood cocentrate such as PRP or platelet releasate) will also depend on the permeation activators, solubilizers, etc. On the free side of the permeable membrane 4 there is a layer of a contact glue 5 (adhesive layer), protected by a release strip 6. During the use of the transdermal patch the release strip 6 is pulled off and the patch is positioned on the desired part of the patient's body, exerting slight pressure. After a "start" phase the flow reaches a constant "saturation" value.

[0072] The patch 1' of (FIG. 5), a matrix or "reservoir" 3, in which the active substance (e.g. blood concentrate such as PRP or platelet releasate) is dissolved and/or dispersed, is applied on the impermeable support film 2'. In the present case the membrane permeable to the active substance, which is used to modify the cross-flow, is missing. The matrix 3' therefore comes into direct contact with the epidermis. The glue 5' is located around the edge of the patch, like an adhesive ring. Everything is protected on the free side by a single release strip 6', which is removable, as for the embodiment of Figure 4.

[0073] The use of the "device" is as follows: the release strip 6' is pulled off and the device is positioned on the desired part of the patient's body, exerting slight pressure.

[0074] The embodiment of Figure 5 can be adopted in particular if the active principle interacts in an unwanted manner with the adhesive, as a result of which it is not possible to mix the adhesive 5' and the active principles in the matrix 3'.

[0075] The pharmacological dose (e.g. blood concentrate such as PRP or platelet releasate) may be placed directly, dissolved or dispersed, into the glue, which thus also becomes a "reservoir" which may be arranged in a layer on a permeable support film. A person skilled in the art reading this disclosure will be able to modify the shape and/or structure of the patch, achieving the best result based on the therapy chosen and the site of application; or on other factors.

[0076] The differences in the structure and shape of the patch (rectangular or anatomical) may be due:

[0077] to the area of skin being treated;

[0078] to the interactions which may exist between the active principle, the glue (different types of adhesive can be used simultaneously), the support material, and other materials such as excipients, stabilizers, etc.;

- [0079] to better stability on the chosen site of application;
[0080] to the dosage (the area of the patch must also increase for a higher dosage).

METHOD OF MANUFACTURE OF THE TRANSDERMAL PATCH

- [0081] 1. The active principle (e.g. blood concentrate such as PRP or platelet releasate) is incorporated simultaneously with the other components (stabilizer, permeation activators, etc.) in the hot adhesive solution and homogenized by stirring, until the liquid adhesive matrix or "reservoir" is obtained;
- [0082] 2. the liquid matrix is cooled, and acquires a "stringy" consistency;
- [0083] 3. the process for layering of the adhesive matrix on the support is carried out using a layering machine which is continuously connected with a drying machine, in the following phases:
- [0084] the blade of a knife is mounted across the entire width of the conveyor belt of the layering machine on which the release strip is securely positioned;
- [0085] the "stringy" adhesive matrix is poured in front of the blade, which, as the conveyor belt advances, distributes a uniform layer (layering) of adhesive matrix on the release strip;
- [0086] the thickness of the layer is mainly determined by the distance between the edge of the knife blade and the release strip running beneath it;
- [0087] the release strip, carrying the adhesive matrix, rotates inside the drying machine, in which the adhesive matrix is solidified by evaporation of the solvent, which is achieved by gradually increasing the temperature and the "ventilation", as shown in the following Table I.

TABLE I

Drying phase	Time (in minutes)	T°C	Vent (rpm)
1	15	40	700
2	20	55	1000
3	25	70	1200

- [0088] The process described allows elimination of the solvent, preventing it from being occluded by the rapid formation of a surface crust.
- [0089] When the adhesive matrix has dried, the support film (backing) is applied. This phase, called "lamination", ends the process.
- [0090] The adhesive should be inert and permeable to the active compound (e.g. blood concentrate such as PRP or platelet releasate), and the adhesive properties of which (cohesion, adhesion and interlacing) are not adversely affected by the blood concentrate such as PRP or platelet releasate itself and/or by excipients or any other material added.

COMPOSITION OF THE PATCH

- [0091] Adhesive Matrix: Formulation
- [0092] active principle: blood concentrate such as PRP or platelet releasate;
- [0093] antioxidant: sodium metabisulphite, EDTA disodium salt;
- [0094] solubilizing agent: a glycol;
- [0095] permeation activator: fatty acids;
- [0096] acrylic resin to improve the cohesive strength: cationic copolymers based on dimethylaminoethylmethacrylate and methacrylic esters;
- [0097] cellulose derivatives to improve the cohesive strength: ethylcellulose;
- [0098] surfactant: SDS (sodium dodecylsulphate);
- [0099] pressure contact adhesive: mixture of two adhesives, A and B, in which A is a non-self-bonding acrylic contact adhesive of medium molecular weight with a high interlacing index, with a skin irritation index of 0.20, classified as "minimally irritating", using 100% ethyl acetate as solvent; and B is a self-bonding acrylic adhesive with a high molecular weight, with moderate interlacing, with a skin irritation index of 0, classified as "non-irritating", using a mixture of ethyl acetate, isopropanol, hexane and toluene as solvent.

RELEASE STRIP

- [00100] The release strip is a polyester film laminated with silicone on one side (that opposite of the adhesive matrix). The thickness is approximately 125 microns.
- [00101] "Backing"

- [00102] The "backing" is a laminated polyester film which is clear and occlusive with a thermoweldable layer. The total thickness is approximately 51 microns.
- [00103] Quantity of Active Principle
- [00104] The quantity of blood concentrate such as PRP or platelet releasate is 5% by weight of the adhesive matrix and corresponds to 5 mg/sq cm. The major part of the blood concentrate such as PRP or platelet releasate is dispersed in the matrix. A minor part is dissolved in the matrix. The active component e.g. blood concentrate such as PRP or platelet releasate dispersed in the matrix acts as a "reservoir", while the active component available for release and permeation is the dissolved active component.
- [00105] Prophetic examples of the patch based with the active component (e.g. blood concentrate such as PRP or platelet releasate) are now given.
- [00106] Two batches of patches of differentiated formulation containing active components are prepared for this purpose.

EXAMPLE A

[00107]	1) platelet releasate	2.20%
[00108]	2) Solubilizing agent	4.00%
[00109]	3) Acrylic resin	29.00%
[00110]	4) Fatty acid 1	3.20%
[00111]	5) Fatty acid 2	1.60%
[00112]	6) Pressure-sensitive adhesive	60.0%

EXAMPLE B

[00113]	1) PRP	4.99%
[00114]	2) EDTA	0.025%
[00115]	3) Solubilizing agent	9.96%
[00116]	4) Fatty acid 1	7.96%
[00117]	5) Fatty acid 2	3.97%
[00118]	6) Acrylic resin	1.99%
[00119]	7) Cellulose derivative	0.25%
[00120]	8) Surfactant	20.4%
[00121]	9) Pressure-sensitive adhesive	50.455%

PATCH DEVOID OF DRUG

[00122] There are a wide range of transdermal patches known in the art and, in general, those patches can be modified to incorporate a platelet releasate formulation of the invention. However, in an embodiment of the invention the platelet releasate is autologous to the patient being treated. To achieve such the patch can be produced without a drug (e.g. without platelet releasate) in it. The patch may have a single or multiple compartments which can be filled with the patient's own platelet releasate prior to placing the patch on the patient's skin. This can be accomplished in a number of different ways. For example, the patch may comprise a compartment which is empty or comprises a gauze, collagen, matrix or like material which readily absorbs a liquid such as releasate formulation of the invention.

[00123] The compartment may be covered by a lid which has a resealable adhesive around its edges. This makes it possible for the lid to be opened, liquid formulation is added to the container and the lid resealed. An alternative is to have a wall or portion of a wall that is comprised of a material that is self sealing when punctured with a hollow cylinder such as a hollow needle used to inject a formulation of the invention into the compartment.

[00124] In accordance with this embodiment of the invention blood is extracted from a patient and platelets of the blood concentrated. The concentrated platelets are subjected to treatment such as sonification to create a platelet releasate. The releasate is formulated to adjust the pH. The pH balanced, liquid, flowable formulation is placed in the compartment. The patient, which may be the patient from which the blood was taken, applies the patch and releasate formulation is administered transdermally. The patch may be in any shape and may, for example, be in the shape of a 3-dimensional mask shaped to fit the face of the patient or a portion of the face of the patient such as over the patient's forehead and around the patient's eyes where wrinkles are most prominent. The patch can be repeatedly applied, night after night, and worn by the patient during sleep and/or just prior to sleep. The releasate is shown to promote the growth of fibroblast cells in the cell

culture of Examples 6 and 7 and fibroblast cells are essential for the young healthy appearance of skin.

[00125] An individualized transdermal patch of the invention can also be used in wound healing. The patch is prepared in a manner as indicated above and applied to a wound. The wound may also be treated with other compounds such as antibodies to aid in the treatment of infection.

INJECTABLE FORMULATIONS

[00126] Injectable formulations may be comprised of PRP, or platelet releasate water and buffer to balance the pH to near physiological pH e.g. about $7.4 \pm 10\%$, $7.4 \pm 5\%$ or 7.2 to 7.6. Suitable formulations of the invention may be prepared using technology as taught within Remington's cited above.

[00127] Both injectable and topical formulations may further comprise fibroblast cells particularly as cultured per the present invention. Both injectable and topical formulations may further comprise PRP releasate and/or other pharmacologically active components.

[00128] In an embodiment of the invention an injectable formulation of collagen conventionally injected into patient's such as to enhance lip fullness is combined with a formulation of the present invention. For example PRP, or platelet releasate is formulated as described herein and combined in an amount of 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%-90% or more by weight with an injectable collagen formulation. The resulting combination may be applied to a wound topically and/or injected into a wound area or area of inflammation. Amounts in a range of 1 to 50cc or 2 to 25cc or 5 to 10cc may be administered.

[00129] In another embodiment of the invention fibroblast cells are added to the formulation comprised of collagen and platelet releasate. The fibroblast cells may be cultured as described here and the platelets and fibroblast cells obtained from the same human patient to which the formulation is injected.

EXAMPLES

[00130] The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the present invention, and are not intended to limit the scope of what the inventor

regard as his invention nor are they intended to represent that the experiments below are all or the only experiments performed. Efforts have been made to ensure accuracy with respect to numbers used (e.g. amounts, temperature, etc.) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Centigrade, and pressure is at or near atmospheric.

Example 1

[00131] PRP was prepared using a centrifuge unit made by Harvest (Plymouth, MA). (Similar units are available as The Biomet GPS system, the Depuy Symphony machine and the Medtronic Magellan machine.) Approximately 55 cc of blood was drawn from the patient using a standard sterile syringe, combined with 5 cc of a citrate dextrose solution for anticoagulation, and then spun down to isolate the platelets according to the manufacturer's protocol. These platelets were then resuspended in approximately 3 cc of plasma. The resulting platelet rich plasma solution (PRP) was quite acidic and was neutralized with using approximately 0.05 cc of an 8.4% sodium bicarbonate buffer per cc of PRP under sterile conditions to approximately physiologic pH of 7.4. The PRP was not activated through addition of exogenous activators. This PRP composition is referred to herein as autologous platelet extract (APEX).

Example 2

[00132] Fifty cc of whole blood is drawn from a patient, and then prepared according to the method of Knighton, U.S. Patent 5,165,938, column 3. The PRP is activated according to Knighton using recombinant human thrombin. The degranulated platelets are spun down and the releasate containing supernatant is recovered. The releasate may be optionally pH adjusted to a pH of 7.4 using sodium bicarbonate buffer.

Example 3

[00133] Thirty ml of whole blood were drawn from a patient. A platelet composition was prepared according to Example 1 of U.S. Patent 5,510,102 to

Cochrum, incorporated herein by reference in its entirety, except that no alginate is added to the platelet composition.

Example 4: Cell Cultures of Any Tissue

[00134] A researcher or clinician wishes to grow a cell culture of either fibroblasts or osteoarthritic cartilage cells. Using the technique of Example 1, an autologous platelet extract (APEX) is obtained and buffered to physiologic pH.

[00135] The cells are then isolated and grown in a media rich in the APEX in various conditions and dilutions. The APEX promotes cell differentiation and production of proteins such as collagen. The APEX may augment or promote the ability of the cells to transform into normal cells. Without intending to be limited by theory, it is hypothesized the APEX may convert the osteoarthritic cartilage cells to a more functional cell line that is reinjected into a diseased or injured joint. Alternatively, the APEX is directly introduced into an osteoarthritic joint to reverse the course of the disease. This is done under local anesthesia in a sterile manner.

Example 5: Human Fibroblast Proliferation in Buffered Platelet Rich Plasma

[00136] Platelet rich plasma has been used to augment bone grafting and to help accelerate or initiate wound healing. Fibroblasts are important components of the wound healing process. This example shows that human fibroblast cells will proliferate more in fetal bovine serum that has been augmented with a proprietary formulation of buffered platelet rich plasma.

[00137] Human fibroblasts were isolated and then put into culture with 10% fetal bovine serum that had been augmented with a proprietary formulation of buffered platelet rich plasma (Group 1) or in 10% fetal bovine serum alone (Group 2). Initial cell counts were 25,000 in both groups.

[00138] Seven days after initiating the culture experiment, the cells in each group were counted. The average total cell count in Group 1 (buffered PRP added) was 1,235,000. The average total cell count in Group 2 (No PRP) was 443,000. The group that was augmented with the buffered platelet rich plasma of the invention had 2.8 times the proliferation of the control group at seven days. (See Figure 1)

[00139] Buffered platelet rich plasma augments human fibroblast proliferation when compared to the use of fetal bovine serum alone. This has significant implications

for the use of buffered platelet rich plasma for either acute or chronic wound healing.

Example 6

Human Fibroblast Proliferation in Sonicated Platelet Rich Plasma

- [00140] Human fibroblasts were isolated and then put into four different cultures. Three of the cultures comprised 10% fetal bovine serum that had been augmented with 9uL, 46uL, and 95uL of buffered and sonicated platelet rich plasma. The fourth served as the control and was comprised of 10% fetal bovine serum. Initial cell counts were 20,000 in both groups. Variable doses of the sonicated PRP (sPRP) were seeded with cells.
- [00141] Four days after initiating the culture experiment, the cells in each of the four groups were counted and the results are shown in Figure 2. The cell count in the control group (No PRP) was 180,000 cells. The cell counts in the sonicated PRP group were as follows: 496,000 (9 uL dose of sPRP), 592,000 (46uL dose of sPRP) and 303,000 (95uL dose of sPRP).
- [00142] This experiment shows that buffered, and sonicated platelet rich plasma augments human fibroblast proliferation when compared to the use of fetal bovine serum alone.

Example 7

Human Fibroblast Proliferation in Sonicated Platelet Rich Plasma

- [00143] Human fibroblasts were isolated and then put into two different cultures. One of the cultures comprised 10% fetal bovine serum that had been augmented with buffered and sonicated platelet rich plasma. The other served as the control and was comprised of 10% fetal bovine serum. Initial cell counts were 20,000 in both groups.
- [00144] Seven days after initiating the culture experiment, the cells in each of the two groups were counted and the results are shown in Figure 3. The cell count in the control group (No PRP) was 183,600 cells. The cell count in the sonicated PRP group was 924,800 cells.

[00145] This experiment shows that buffered, and sonicated platelet rich plasma augments human fibroblast proliferation when compared to the use of fetal bovine serum alone. These results show the ability of the platelet releasate to promote cell growth and in particular fibroblast cells which are essential to firm, young looking skin.

[00146] The preceding merely illustrates the principles of the invention. It will be appreciated that those skilled in the art will be able to devise various arrangements which, although not explicitly described or shown herein, embody the principles of the invention and are included within its spirit and scope. Furthermore, all examples and conditional language recited herein are principally intended to aid the reader in understanding the principles of the invention and the concepts contributed by the inventor to furthering the art, and are to be construed as being without limitation to such specifically recited examples and conditions. Moreover, all statements herein reciting principles, aspects, and embodiments of the invention as well as specific examples thereof, are intended to encompass both structural and functional equivalents thereof. Additionally, it is intended that such equivalents include both currently known equivalents and equivalents developed in the future, i.e., any elements developed that perform the same function, regardless of structure. The scope of the present invention, therefore, is not intended to be limited to the exemplary embodiments shown and described herein. Rather, the scope and spirit of present invention is embodied by the appended claims.

CLAIMS

That which is claimed is:

1. A method of treatment, comprising:
isolating a blood component from a patient;
formulating the isolated blood component into a pH balanced formulation;
administering the formulation to a site of surgical incision.
2. The method of claim 1, wherein the blood component is platelets.
3. The method of claim 2, wherein the platelets are subjected to processing to obtain platelet releasate.
4. The method of claim 3, wherein the formulation is administered to the site prior to making a surgical incision.
5. The method of claim 3, wherein the formulation is administered to the site while the incision is being made.
6. The method of claim 3, wherein the formulation is administered to the site after the incision is made.
7. The method of claim 3, wherein the formulation is administered to the site before, during and after making the surgical incision.
8. The method of claim 6, wherein the formulation is repeated administered to the site after the incision is made.
9. The method of claim 6, wherein the repeated administered are once a day over a plurality of days.
10. A method of performing a surgical operation, comprising:
making a surgical incision in a patient; and

applying to the incision a formulation comprising platelet releasate obtained from blood of the same patient the incision is made in.

11. The method of claim 1, wherein the incision is made in the course of an appendectomy, tonsillectomy, hernia removal, ulcer excision, scalp incision for hair transplant, laser skin ablation, vessel anastomosis, a heart valve procedure, liposuction procedure, and face lift procedure.

12. A composition, comprising:
collagen of a type suitable for injection into a human; and
a component isolated from human blood.

13. The composition of claim 12, wherein the component isolated from human blood is platelets.

14. The composition of claim 12, wherein the component isolated from human blood is platelet releasate.

15. The composition of claim 12, further comprising:
fibroblast cells.

16. The composition of claim 13, further comprising:
fibroblast cells obtained from the same human patient as the platelets are obtained from.

17. A method of treatment, comprising:
administering to a human patient a formulation comprising collagen and platelet releasate;
allowing the formulation to effect the area of administration in the patient.

18. The method of claim 17, wherein the formulation further comprises fibroblast cells.

19. The method of claim 18, wherein the platelet releasate and fibroblast cells are obtained from the same patient to which the formulation is administered.

20. The method of claim 17, wherein the formulation is injected into the patient.

21. The method of claim 17, wherein the formulation is applied to a site of a surgical incision.

22. The method of claim 21, wherein the incision is made in the course of an appendectomy, tonsillectomy, hernia removal, ulcer excision, scalp incision for hair transplant, laser skin ablation, vessel anastomosis, a heart valve procedure, liposuction procedure, and face lift procedure.

BUFFERED PLATELET RELEASATE TO ENHANCE WOUND HEALING

ABSTRACT OF THE DISCLOSURE

[00147] A concentrated component of blood such as platelets are sonicated and formulated into a pH balanced formulation. The formulation is applied to a site of inflammation or wound such as a surgical incision to increase the site of healing and decrease the inflammatory response. The platelets may be obtained from the same patient who's wound is being treated.

F:\DOCUMENT\AMBI\005prv\AMBI-005PRV - appln.doc

FIG. 1

Human Fibroblast Proliferation




FIG. 2

Human Fibroblast Culture in Sonicated PRP





FIG. 3

Human Fibroblast Proliferation



APPLICATION INFORMATION

Application Type::	Provisional
Title::	BUFFERED PLATELET RELEASATE TO ENHANCE WOUND HEALING
Attorney Docket Number::	AMBI-005RV
Request for Non-Publication?::	No
Assignee for Publication::	AM Biosolutions
Total Drawing Sheets::	3
Small Entity?::	Small
License US Govt. Agency::	No
Contract or Grant Numbers::	N/A
Sequence Submission?::	No
Computer Readable Form (CRF)?::	No

INVENTOR INFORMATION

Inventor One Given Name::	Allan
Family Name::	Mishra
Postal Address Line One::	1312 Orange Avenue
Postal Address Line Two::	
City::	Menlo Park
State or Province::	California
Postal or Zip Code::	94025
Citizenship Country::	USA

Inventor Two Given Name::
Family Name::
Postal Address Line One::
Postal Address Line Two:
City::
State or Province::
Postal or Zip Code::
Citizenship Country::

Inventor Three Given Name::
Family Name::
Postal Address Line One::
Postal Address Line Two::
City::
State or Province::
Postal or Zip Code::
Citizenship Country::

CORRESPONDENCE INFORMATION

Correspondence Customer Number:: 24353
Telephone One:: (650) 327-3400
Telephone Two:: (650) 833-7735
Fax:: (650) 327-3231
Electronic Mail:: bozicevic@bozpat.com

REPRESENTATIVE INFORMATION

Representative Customer Number:: 24353

CONTINUITY INFORMATION

This application:: Claims priority to
> Application One:: PCT/US03/11623
Filing Date:: April 14, 2003

which application:: Claims the benefit of priority to
> Application Two:: 60/372,682
Filing Date:: April 13, 2002

And:: Claims the benefit of priority to
>> Application Three:: 10/412,821
Filing Date:: April 11, 2003

which is a::
>>> Application Four::
Filing Date::

PRIOR FOREIGN APPLICATIONS

Foreign Application One::
Filing Date::
Country::
Priority Claimed::